肺肿瘤多组学分析揭示神经内分泌转化激活通路
该研究对肺腺癌/小细胞肺癌混合肿瘤及转化前后样本进行基因组、表观基因组、转录组和蛋白表征,发现神经内分泌转化主要由转录重编程驱动而非突变事件,并识别3p染色体臂缺失等易感基因组背景及PRC2、PI3K/AKT、NOTCH通路表达增强。在EGFR突变患者来源异种移植模型中,药理学抑制PI3K/AKT通路延缓肿瘤生长和神经内分泌转化。
要点
- 神经内分泌转化主要由转录重编程驱动,而非突变事件。
- 3p染色体臂频繁缺失是神经内分泌转化易感的基因组背景。
- 抑制PI3K/AKT通路可延缓EGFR突变模型中的肿瘤生长和神经内分泌转化。
核心结论
- 神经内分泌转化主要由转录重编程驱动而非突变事件,并涉及PRC2复合体、PI3K/AKT和NOTCH通路表达增强。
研究设计与样本
- 对肺腺癌/小细胞肺癌混合肿瘤及转化前后临床样本进行基因组、表观基因组、转录组和蛋白多组学表征。
- 在EGFR突变患者来源异种移植模型中测试PI3K/AKT通路药理学抑制的效果。
主要发现
- 神经内分泌转化主要由转录重编程驱动而非突变事件。
- 神经内分泌转化易感的基因组背景包括3p染色体臂频繁缺失。
- 转化样本中PRC2复合体、PI3K/AKT和NOTCH通路相关基因表达增强。
- 在EGFR突变患者来源异种移植模型中,PI3K/AKT通路药理学抑制延缓肿瘤生长和神经内分泌转化。
临床怎么用
- 关注3p染色体臂缺失等基因组背景以识别神经内分泌转化易感患者。
- PI3K/AKT通路抑制可能作为延缓EGFR突变肺腺癌神经内分泌转化的治疗策略。
局限性
- 转化前后临床样本稀缺限制了分子分析的开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer. SIGNIFICANCE: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung. See related commentary by Meador and Lovly, p. 2962. This article is highlighted in the In This Issue feature, p. 2945.
引用
- Quintanal-Villalonga A, Taniguchi H, Zhan YA, et al. Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discov. 2021. PMID: 34155000. doi:10.1158/2159-8290.CD-20-1863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。